What is the medical insurance reimbursement amount for Delamanid?

Delamanid is a new anti-tuberculosis drug for patients with multidrug-resistant tuberculosis (MDR-TB). It is a triazole compound that inhibits the nitro reduction process in the cell wall of Mycobacterium tuberculosis, interfering with the growth and reproduction of bacteria, thereby achieving antibacterial effects. Its introduction provides an important treatment option for patients with MDR-TB, especially those who have failed previous treatments or are resistant to multiple conventional drugs. Delamanid is often used in combination with other anti-tuberculosis drugs, such as rifampin, isoniazid or aminoglycosides, to form a multi-drug regimen to improve treatment success and reduce the risk of drug resistance.

In China, Delamani has been approved for marketing and included in the scope of Class B medical insurance, but medical insurance reimbursement is limited to confirmed multi-drug-resistant tuberculosis patients, which means that ordinary tuberculosis patients cannot enjoy medical insurance reimbursement. The common drug specifications are 50mg*60 tablets per box, and the market price is about more than 6,000 yuan. The actual reimbursement amount for each patient will vary according to the medical insurance policy in the region, but it can usually cover most of the drug costs, significantly reducing the patient's financial burden and improving treatment compliance.

When using delamanid, patients should strictly follow the doctor's instructions, take it according to the prescribed dosage and course of treatment, and avoid adjusting the dosage or stopping the medicine early. During treatment, liver function, renal function and electrocardiogram need to be monitored regularly, and possible adverse reactions should be paid attention to, such as mild liver function abnormalities or QT interval prolongation. Patients and their families should maintain close communication with their doctors and report abnormal symptoms in a timely manner so that treatment plans can be adjusted.

The clinical application of delamanid not only enriches the treatment options for multi-drug-resistant tuberculosis, but also reflects the public health policy's emphasis on drug-resistant tuberculosis. Through medical insurance reimbursement, patients can obtain financial support, improve long-term treatment compliance, and at the same time provide an effective tool for domestic multi-drug-resistant tuberculosis prevention and control.

Reference: https://go.drugbank.com/drugs/DB11637